Skip to content

Reducing Barriers to Lifestyle Modification for Newly Diagnosed MASLD

Reducing Barriers to Lifestyle Modification for Pediatric Patients of Hispanic Ethnicity and Newly Diagnosed MASLD

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06483711
Enrollment
50
Registered
2024-07-03
Start date
2025-07-01
Completion date
2027-07-30
Last updated
2025-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Dysfunction-associated Steatotic Liver Disease

Brief summary

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of liver disease in the world. It is estimated that 38% of American children with obesity have steatotic liver disease. Patients of Hispanic ethnicity are disproportionately at risk of developing MASLD. This study intends to provide insight to barriers of recommended care for pediatric patients with Hispanic ethnicity and a new diagnosis of MASLD. The investigators propose to augment existing structural barriers related to health literacy, food accessibility and dietary knowledge, and access to safe physical activity through a healthy lifestyle toolkit and individualized nutritional counseling.

Detailed description

The Hispanic population represents the largest and fastest growing ethnic group in the United States. Patients of Hispanic ethnicity are disproportionately at risk of developing MASLD. An adult meta-analysis found a prevalence rate of 22.9% among individuals of Hispanic ethnicity. A pediatric retrospective study found that children who are Hispanic are 5 times more likely to have MASLD than their age/gender matched peers who identify as black. The etiology of why individuals of Hispanic ethnicity are at higher risk of developing MASLD, and subsequently associated co-morbidities such as insulin resistance, diabetes, and cardiovascular disease, is thought to be multifactorial. There is evidence to suggest that individuals of Hispanic ethnicity have a genetic predisposition for hepatic fat infiltration.11 Additionally, it has been postulated that social determinants of health, such as economic stability and health care access and quality contribute to an increased risk. The American Association for the Study of Liver Diseases (AASLD) recommends lifestyle modification as the foundation of treatment for MASLD. Implementing dietary changes and increasing physical activity contribute to weight loss, which has been found to reduce hepatic steatosis. A 7-10% weight loss can improve histopathological features of MASLD, including fibrosis.Application of dietary modification, such as adherence to the Mediterranean dietary pattern, can decrease hepatic fat content, even in the absence of weight loss.Though lifestyle intervention has been found to be effective, barriers to implementation exist. In a study of adult patients of Hispanic ethnicity with a diagnosis of MASLD, access to nutritious food and a safe exercising environment limited the ability to follow through with recommended lifestyle changes.A survey study of pediatric patients with MASLD found that many lacked the opportunity for physical activity, though the majority expressed an interest in participation.16 Health literacy, or the ability to obtain and comprehend medical information, has also been found to be a barrier to effective care. In a qualitative interview study of adults with MASLD, health literacy was hindered by the availability of liver disease resources in the patient's preferred language. There is limited pediatric data regarding perceived barriers to implementing lifestyle changes. With this study, the investigators hope to minimize some of the social determinants of health that can impact Hispanic pediatric MASLD patients and help them participate in the recommended standard of care.

Interventions

OTHERLifestyle Kit

The investigators will provide a kit to families that contains educational information, exercise equipment, and nutritional products.

Sponsors

Stanford University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
10 Years to 17 Years
Healthy volunteers
No

Inclusion criteria

* Pediatric and adolescent patients age 10-17 years of Hispanic ethnicity and newly diagnosed MASLD (as confirmed by ultrasound or biopsy + cardiometabolic risk factor) in the pediatric hepatology or GI clinic. Patients will also be restricted to patients who live in Alameda, Contra Costa, Solano, San Francisco, San Mateo, and Santa Clara counties due to the limitations of Fresh Approach locations. Families that include one family member who speaks English.

Exclusion criteria

* Age less than 10 and age greater than 17. Patient who do not live in Alameda, Contra Costa, Solano, San Francisco, San Mateo, and Santa Clara counties due to limitations of Fresh Approach locations. Families with no English Speakers or families whose primary language is not English or Spanish.

Design outcomes

Primary

MeasureTime frameDescription
Number of Social Determinants of Health Impacting ParticipantsBaseline and month 3 or 6 depending on when the participant's follow up appointment with the physician is scheduled.Social Determinants of Health Screener will identify the presence of food, housing, and/or transportation insecurity.

Secondary

MeasureTime frameDescription
Mean Change from Baseline ALT at 3 or 6 month follow-up appointmentBaseline and month 3 or 6 depending on when the participant's follow up appointment with the physician is scheduled.ALT Lab value
Mean Change from Baseline GGT at 3 or 6 month follow-up appointmentBaseline and month 3 or 6 depending on when the participant's follow up appointment with the physician is scheduled.GGT Lab value
Mean BMI Change from Baseline at 3 or 6 month follow-up appointmentBaseline and month 3 or 6 depending on when the participant's follow up appointment with the physician is scheduled.BMI
Mean Change from Baseline AST at 3 or 6 month follow-up appointmentBaseline and month 3 or 6 depending on when the participant's follow up appointment with the physician is scheduled.AST lab value
Socioeconomic status of Participants participating in the studyBaseline and month 3 or 6 depending on when the participant's follow up appointment with the physician is scheduled.Socioeconomic status
Ethnic background of Participants participating in the studyBaseline and month 3 or 6 depending on when the participant's follow up appointment with the physician is scheduled.ethnic background
Primary language of Participants participating in the studyBaseline and month 3 or 6 depending on when the participant's follow up appointment with the physician is scheduled.primary language
Mean Weight Change from Baseline at 3 or 6 month follow-up appointmentBaseline and month 3 or 6 depending on when the participant's follow up appointment with the physician is scheduled.weight

Contacts

Primary ContactRachel Herdes, DO
rherdes@stanford.edu650-497-8911
Backup ContactAmrita Narang, MD
anarang@stanford.edu650-497-8911

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026